Orexo, AB v. Actavis Elizabeth LLC
United States Court of Appeals for the Federal Circuit
2018 WL 4288961 (2018)
Relevant factsFree
Zubsolv's patent used citric-acid particles as a novel carrier for buprenorphine particles, unlike prior drugs such as Suboxone, achieving improved bioavailability and abuse deterrence; Actavis, seeking to market a generic version, argued obviousness based on prior patents disclosing the individual ingredients and a separate patent using citric acid to increase bioavailability in a different way, and the trial court agreed the combination would have been obvious.
IssueFree
Whether a formulation is obvious even if the components of the formulation are referenced in prior art, if the prior art did not suggest the selection and combination achieved by the formulation.
Related cases
Experian Information Solutions, Inc. v. Nationwide Marketing Services, Inc.893 F.3d 1176 (2018)Oil States Energy Services, LLC v. Greene's Energy Group, LLC138 S. Ct. 1365 (2018)Cohen v. G & M Realty L.P.125 U.S.P.Q.2d 1708 (2018)Baldwin v. EMI Feist Catalog, Inc.805 F.3d 18 (2d Cir. 2018)Adidas America, Inc. v. Skechers USA, Inc.890 F.3d 747 (2018)